Labcorp Holdings Inc. (LH)

Over the past six months, Labcorp's stock price has experienced movement and analyst attention. As of July 16, 2025, the share price was $245.98, representing a 14.00% increase over the past year. Key events include strong Q4 2024 and Q1 2025 earnings reports, positive analyst ratings with a consensus of "Strong Buy", strategic initiatives to strengthen its position in key growth areas, and a quarterly cash dividend declaration of $0.72 per share.

While specific detailed information on demand seasonality for all Labcorp products and services is not explicitly provided, the company's financial reporting indicates some general trends. Labcorp's free cash flow is expected to be weighted towards the second half of the year due to normal seasonality. The company's Diagnostics Laboratories business experienced a 6% growth in Q1 2025, and overall volume growth in diagnostics has been higher than historical averages, suggesting a consistent demand for its testing services.

Labcorp Holdings, Inc. is a global life sciences company based in Burlington, North Carolina, operating in the healthcare sector, specifically in diagnostics and research. The company provides laboratory services to assist healthcare decisions. Labcorp operates through two segments: Labcorp Diagnostics, which offers a wide array of laboratory testing services, and Labcorp Biopharma Drug Development, which provides drug development support services.

Labcorp has a significant global presence, serving clients in over 100 countries, with primary operations in the United States. It operates one of the largest clinical laboratory networks worldwide, including manufacturing facilities in the U.S., Belgium, China, Japan, India, Germany, Singapore, the UK, and Switzerland. Recent expansions include new kit production and immunology/immunotoxicology labs in China, enhanced central laboratory presence in Japan, and expanded anatomic pathology and histology laboratories in Singapore, Switzerland and Japan. In the U.S., its Diagnostics Laboratories segment operates 2,000 patient service centers with over 6,000 in-office phlebotomists.

Labcorp has a strong brand reputation within the life sciences and healthcare industries. It was named to FORTUNE magazine's "World's Most Admired Companies" list for the second consecutive year in 2019. The company's strategic focus on innovation and customer service has enhanced its reputation and reliability among healthcare professionals and patients. Labcorp's large scale, diversified business model, strong industry relationships, and operational efficiency contribute to its competitive advantages and brand recognition.

Labcorp Holdings Inc. is predominantly owned by institutional shareholders, who hold 91.62% of the company's shares. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Individual ownership accounts for 1.53% by Labcorp insiders and 6.85% by retail investors.